Areas of Interest & Competitive Research Grants

Areas of Interest (AOI)

We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.

Therapeutic Area and / or Compound AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Immunology – Abatacept (Orencia) 19-Sep-22 31-Oct-22 01-Dec-22
Immunology – Zeposia UC (Ozanimod) 28-Nov-22 02-Jan-23 19-Jan-23
Immunology – Zeposia MS (Ozanimod) 20-Mar-23 01-May-23 18-May-23


Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.

Begin a New Application